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ABSTRACT
Type 2 diabetes is a progressive disease where in case of 
unsuccessful behavioral modifications and metformin 
monotherapy treatment needs to be intensified by add-
ing some other oral agents and/or GLP-1 agonists and/ 
/or basal insulin. After some years of treatment with 
increasing defect of beta cells, there is a necessity to 
start or intensify insulin therapy with prandial insulin, 
premixed insulin, basal-bolus regimen or multiple injec-
tions of insulin. Patient’s treatment should be individu-
alized but there are no direct recommendations which 
type of insulin to choose — human or analogue one. 
This article summarizes clinical situations in which one 
could consider using human insulin. When selecting 
a suitable insulin, the type of dietary habits, especially 
eating snacks, the presence of gastroparesis and eco-
nomic issues should be taken into account. It turnes 
out that for patients with type 2 diabetes both human 
and analogue insulins are equally safe and efficient in 
terms of risk of severe hypoglycaemia. Undoubtedly, 
analogue insulin has uncontestable advantages, but in 
some clinical cases human insulin seems to be a better 
option. (Clin Diabetol 2018; 7, 3: 171–174)
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Introduction
The number of patients with type 2 diabetes, 
a disease named the non-infectious epidemic of the 
21-st century, continues to increase year over year. 
With each issue, the periodic reports by the IDF — In-
ternational Diabetes Federation — convey worsening 
statistical data concerning the prevalence of diabetes 
worldwide. Up to date statistics show that the num-
ber of diabetic patients will increase from 425 million 
in the year 2017 to 629 million in the year 2045 [1]. 
Due to a progress in antidiabetic medications used, 
as well as multimodal treatment of diabetic patients, 
the average life expectancy of a diabetic patient has 
increased. Consequently, both duration of the disease 
and the time in which the individual, target values of 
glycaemia need to be maintained, have also grown. 
In case of unsuccessful behavioral modifications and 
metformin monotherapy, there is a need to intensify 
the treatment by adding some other oral agents and/or 
GLP-1 agonists and/or basal insulin. After some years of 
treatment with increasing defect of beta cells, there is a 
necessity to start prandial insulin therapy as premixed 
insulin, basal-bolus regimen or multiple injections [2, 3]. 
Since the first use of insulin in 1922, a steady progress 
in pharmacokinetics and pharmacodynamics of insulin 
medications has been observed. We have classical hu-
man insulins, insulin analogues and biosimilar insulins 
at our disposal, differing in onset, peak and duration of 
action, as well as the therapy cost. Nevertheless, many 
patients still fail to reach target glycemic values [4]. 
This motivates further efforts to develop newer insulin 
medications, in order to improve glycaemic control 
and reach the physiological ideal insulin action [5]. In 
a view of the constantly increasing number of diabetic 
patients, those who use insulin among them, as well 
as the individual and social costs of therapy, a question 
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must be asked — what criteria should be applied in 
choosing the insulin for a type 2 diabetic patient [6–8]?
Human or analogue insulin? 
Both polish and international diabetic associations 
agree that the treatment of diabetes should be, above 
all, individualized [6, 7] and not only efficient, but also 
safe and without negative effect on the patient’s quality 
of life [8]. It is recommended for type 2 diabetic patients 
to maintain target values of HbA1c below or equal to 
7%. However, these recommendations do not state 
which kind of insulin — human or analogue — should 
be used, leaving the choice to the physician, in accord-
ance with patient’s individual needs and preferences. 
While choosing the therapy, one should consider the 
patient’s lifestyle and alimentary habits regarding the 
quality and frequency of meals, the risks and occurrence 
of hypoglycemic episodes, as well as the cost of the 
treatment. In case of type 2 diabetic patients, research 
comparing prandial insulin analogues and human 
insulins does not show an unambiguous difference 
in reaching better glycaemic control or reducing the 
risk of hypoglycemic episodes between the discussed 
treatment modalities. The advantages of rapid acting 
analogue insulin are the possibility of using it during or 
even after the meal, the chance to reduce the number 
of meals or snacks, lower increase in body mass and 
less episodes of hypoglycemia in the late postprandial 
period or during the night [9]. 
In comparison to NPH insulin, the long lasting 
analogue insulin has been proved to reduce the risk 
of occurrence of any hypoglycemia and nighttime 
hypoglycemia. Additional benefits are the option 
to treat with a single injection only and a peak-less 
hypoglycemic effect, combined with low absorption 
variability in individual patients, as well as between 
different patients [9, 10]. 
Insulin therapy in type 2 diabetes is most fre-
quently initiated with basal insulin — ispophane NPH or 
a long-acting insulin analogue — administered once 
a day [6]. In Poland, long-acting insulin analogues 
are reimbursed for type 2 diabetic patients only after 
a 6-month period of treatment with insulin NPH and 
having met specific reimbursement criteria [11]. Howev-
er, there is a large group of patients who cannot afford 
the cost of an long-acting insulin analogue therapy, 
despite having met the criteria for reimbursement. 
For these patients, NPH insulin is the only acceptable 
therapeutic option [12].
The introduction of premixed insulin, basal-bolus 
scheme or even multiple injections of insulin may be 
considered when basal insulin is used in the dose ex-
ceeding 30 IU a day with poor metabolic control, or 
when introduction of insulin treatment was postponed 
and resulted in a significant hyperglycemia with HbA1c 
levels exceeding the therapeutic goals [6]. A variety of 
premixed human insulin preparations with different 
proportions of rapid-acting and long-acting insulin 
are available in Poland. This gives the opportunity to 
flexi ble selection of the appropriate insulin with a wider 
therapeutic options comparing to insulin analogues.
Aside from the basal-plus or basal-bolus regimens 
of insulin therapy, the premixed insulin regimen may 
be a next step in intensifying insulin therapy, when 
basal insulin therapy becomes insufficient [8]. Both 
human and analogue premixed insulin contain a fixed 
ratio of short/rapid acting to long-acting insulin what 
on one hand provides prandial and basal insulin in 
a single injection but on the other hand reduces the 
unlimited modifications of insulin dosage and time of 
administration, enforcing regularity of injections and 
similar quality of ingested meals [13]. For patients who 
are not able to give up snacks, premixed human insulin 
may be a more beneficial therapeutic choice because of 
the longer total time of action. Moreover, there is no 
convincing evidence for better safety or/and effective-
ness of human or analogue insulin. The final choice of 
insulin preparation should be made individually, taking 
the patient’s preference regarding the number of meals 
and therapy costs into consideration [12]. 
The premixed insulin therapeutic regimen is one 
of the most commonly used in many countries [14]. 
Yet, results of studies comparing the effectiveness of 
premixed human insulin to premixed insulin analogues 
have not assessed switching premixed insulin analogue 
therapy to human one. For this reason, we conducted a 
large, observational study PORGENS BENEFIT — includ-
ing 3264 type 2 diabetes patients. To our knowledge, 
this is the first study assessing the efficiency, safety 
and quality of treatment satisfaction of patients using 
premixed insulin analogues, in comparison to patients 
who switched to human premixed insulin because of 
poor metabolic control and/or patient’s preference. The 
outcomes of the study proved that both therapeutic 
options are safe and efficient, and the patients are 
satisfied with the applied treatment [15].
One of the clinical situations in diabetes, in which 
the use of human insulin over analogue insulin seems 
to be beneficial is diabetic autonomic neuropathy of 
the digestive system.
Referenced data shows that delayed gastric emp-
tying occurs in 25–55% of type 1 diabetic patients and 
in approximately 30% of type 2 diabetic patients [16]. 
The occurrence of gastroparesis greatly hinders efficient 
diabetes treatment, causing the use of oral medications 
impossible and becomes an indication for introducing 
Katarzyna Nabrdalik et al., Human insulin — a place in the therapy
173
insulin therapy. Treatment of patients with diabetic 
autonomic neuropathy of the digestive system is not 
an easy task because food absorption is delayed and 
often unpredictable. In case of using insulin analogues, 
a postpriandal hypoglycemia may occur, followed by 
hyperglycemia caused by delayed absorption of nutri-
ents and the rebound effect. Therefore, short-acting 
human insulin is an optimal therapeutic choice in these 
cases, as its pharmacokinetics and pharmacodynamics 
allows a better control of postprandial glycaemia [17].
Clinicians face the choice of an optimal insulin type 
not only in outpatients clinics, but also in emergency 
cases, like ketoacidosis, and in the following recovery 
period. In 2009 G. Umpierrez et al. conducted a multi-
center, randomized study on a group of 74 patients 
with diabetic ketoacidosis treated with intravenous 
infusions of human or analogue insulin. The treat-
ment was then continued respectively with NPH insulin 
combined with short acting human insulin, or with 
long-acting insulin analogue combined with rapid-
acting insulin one. No differences in doses of insulin 
or time necessary to treat acidosis were observed in 
relation to the kind of insulin used. However, it must be 
stated, that after the acute phase of decompensation 
of diabetes, the use of analogue insulin was related to 
lower rate of hypoglycemic episodes occurrence [18].
Furthermore, given the increasing accessibility of 
modern therapeutic methods such as personal insulin 
pumps — which are also used in some type 2 diabetes 
patients — we should contemplate the role of human 
insulin in these cases. Rapid acting insulin analogues are 
most commonly used in treatment with personal insulin 
pumps. Nonetheless, some reported cases describe the 
occurrence of lipoatrophy at the injection site, when 
analogues were administered in a continuous infusion. 
This pathology did not progress after switching the 
medication to human short acting insulin [19].
Summary
Since different types of insulin — human, analogue 
and biosimilar ones are available on the market — the 
treatment can be personalized. There are, however, 
some clinical situations in type 2 diabetes — in which 
the therapy regimen with human insulin seem to be 
an equal, or even a better choice. These include dif-
ferent lifestyle and alimentary habits, mainly snacking 
between main meals, and presence of gastroparesis 
but also — in case of long-acting insulin — economic 
factors, limiting its use beyond the reimbursement 
policy. In Poland, the financial aspect had been a com-
mon cause of treating patients — even those with type 
1 diabetes — with short acting human insulin. Since 
the introduction of biosimilar, rapid acting insulin ana-
logues, its price is comparable to the price of human 
insulin. However, as was mentioned above, a major 
difference between the cost of human and analogue 
basal insulin is still present. 
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